NEMESIS – “Novel Effect biomarkers for MEtabolic disruptorS: evidence on health Impacts to answer science and policy needS”
The NEMESIS consortium addresses the regulatory challenges of endocrine-disrupting chemicals (EDCs), which interfere with lipid and glucose metabolism, contributing to obesity, atherosclerosis, and type 2 diabetes. EDCs can have long-lasting effects, yet their metabolic impacts remain poorly understood due to a lack of data.
Bringing together experts from various fields, NEMESIS will collect comprehensive data through in silico, in vitro, in vivo, and epidemiological studies to assess how EDCs affect metabolic functions in the liver, pancreas, and gut microbiota. The project aims to identify biomarkers of metabolic disruption and develop Adverse Outcome Pathways (AOPs) and Integrated Approaches to Testing and Assessment (IATA) to improve risk assessment.
Additionally, NEMESIS emphasizes citizen engagement to enhance risk communication about EDCs and ensure the findings effectively inform policy.
For more information about this project, click here.
